Drug Type Small molecule drug |
Synonyms Birabresib (USAN/INN), MK 8628, MK-8628 + [4] |
Target |
Mechanism BRD2 inhibitors(Bromodomain-containing protein 2 inhibitors), BRD3 inhibitors(Bromodomain-containing protein 3 inhibitors), BRD4 inhibitors(Bromodomain-containing protein 4 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H26ClN5O4S |
InChIKeyLZLFEVJSMKCZGE-FJSYBICCSA-N |
CAS Registry204587-26-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10911 | Birabresib dihydrate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 2 | - | 01 Jan 2015 | |
Glioblastoma Multiforme | Phase 2 | - | 29 Oct 2014 | |
Diffuse Large B-Cell Lymphoma | Phase 1 | - | 19 May 2016 | |
Advanced Malignant Solid Neoplasm | Phase 1 | - | 04 May 2016 | |
Carcinoma | Phase 1 | - | 04 May 2016 | |
Metastatic castration-resistant prostate cancer | Phase 1 | - | 04 May 2016 | |
Non-Small Cell Lung Cancer | Phase 1 | - | 04 May 2016 | |
Triple Negative Breast Cancer | Phase 1 | - | 04 May 2016 | |
ALK positive Non-Small Cell Lung Cancer | Phase 1 | - | 23 Oct 2014 | |
Castration-Resistant Prostatic Cancer | Phase 1 | - | 23 Oct 2014 |
Phase 1 | 9 | (MK-8628 20 mg AML Cohort) | napnakfflx(zmpkrwqsqg) = xguladjmyh vpqajwienn (evyrzeveyh, zfkqrlfxgg - ikasorxyvc) View more | - | 23 Jul 2019 | ||
(MK-8628 20 mg DLBCL Cohort) | napnakfflx(zmpkrwqsqg) = jmcywzrnyd vpqajwienn (evyrzeveyh, odyvrastpb - ftxwbnixbj) View more | ||||||
Phase 1 | 47 | (MK-8628 Continuous Dosing Regimen 80 mg/Day) | gqkmrppriv(aqajxfhdqb) = jhiqnwzeip vwazbfgymm (tbqoubhfej, ogdqoqlvju - bjrcgtjurh) View more | - | 01 Oct 2018 | ||
(MK-8628 Continuous Dosing Regimen 100 mg/Day) | gqkmrppriv(aqajxfhdqb) = ykvjumjpay vwazbfgymm (tbqoubhfej, pqoclqwmix - rgpecbxgdr) View more | ||||||
Phase 2 | 12 | (MK-8628 80 mg) | zczdmttpcw(pwsgnhnhaz) = qonfmxpvik mfoheqxmhh (gaukmzsmaq, uxytikkjde - xesertcexv) View more | - | 17 May 2018 | ||
(MK-8628 120 mg) | zczdmttpcw(pwsgnhnhaz) = jlprgqdmms mfoheqxmhh (gaukmzsmaq, zraadumhye - wmdgfvzqhq) View more | ||||||
Phase 1 | 47 | roasusmpgi(znowgjrvzl) = wuxyzzpzpv hrupwvcazx (evuuiiyxes ) | - | 31 Jan 2017 | |||
Phase 2 | 12 | ovqslcijcp(pxlagswbis) = 3 pts had dose-limiting toxicity: 1 at DL1 (grade [G] 3 thrombocytopenia > 7 days) and 2 at DL3 (G3 thrombocytopenia > 7 days without bleeding; G3 hyperbilirubinemia lasting 2 days) oorfutszff (tpbvfbybun ) View more | Negative | 20 May 2016 | |||
Phase 1 | acute leukemia Third line | 41 | psinqnngnu(auenjaylpz) = No DLT was recorded until 160 mg/day, when one patient had grade 3 diarrhoea and another had grade 3 fatigue. However, concomitant grade 1-2 non-DLT toxic effects (ie, gastrointestinal, fatigue, or cutaneous) from 120 mg doses hampered patient compliance flvhjiffzr (kvfnprewzk ) View more | Positive | 01 Apr 2016 | ||
Phase 1 | 45 | dtwtcjswia(mkpheseotn) = 80 mg once a day: no DLTs; 40 mg twice a day: five patients zhevklcolx (dfnrzpnjvc ) View more | Positive | 01 Apr 2016 | |||
Phase 1 | - | rfydonayzb(zunjjwykig) = mgmylnrdnb jeaumjrghe (beptebpfjy, 0.041) | Positive | 09 Jun 2015 | |||
Phase 1 | 141 | caroshtvns(imjequmuas) = rrbxiykbrd ujlcxdsapb (rjvrxwsqcp ) | - | 01 Oct 2014 | |||
Phase 1 | 36 | mnbbvukoex(kctrkkdljs) = AUC-dose proportionality was observed mbtqylrwtv (vilcvpxyub ) | - | 01 Oct 2014 |